OBIETTIVI
The objective is the understanding of the molecular pathogenesis and the evaluation of the efficacy of the treatment with B6 vitamers of gyrate atrophy (GA), a rare disease due to mutations in the gene encoding the pyridoxal 5'-phosphate-dependent enzyme ornithine aminotransferase (OAT).
OBIETTIVI
The objective is the understanding of the molecular pathogenesis and the evaluation of the efficacy of the treatment with B6 vitamers of gyrate atrophy (GA), a rare disease due to mutations in the gene encoding the pyridoxal 5'-phosphate-dependent enzyme ornithine aminotransferase (OAT).
OBIETTIVI
The objective is the understanding of the molecular pathogenesis and the evaluation of the efficacy of the treatment with B6 vitamers of gyrate atrophy (GA), a rare disease due to mutations in the gene encoding the pyridoxal 5'-phosphate-dependent enzyme ornithine aminotransferase (OAT).
